Compare Hormel Foods Corp (HRL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Neurocrine Biosciences Inc — how do they compare? Hormel Foods Corp trades at $24.39 (market cap $13.37B), while Neurocrine Biosciences Inc trades at $151.32 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Hormel Foods Corp pays a 4.81% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HRL | NBIX | |
|---|---|---|
Market Cap | $13.37B | $16.46B |
Sector | Consumer Staples | Health |
52-Week High | $29.25 | $185.50 |
52-Week Low | $19.74 | $123.10 |
Enterprise Value | $15.37B | $16.48B |
Dividend Yield | 4.81% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
